Clinical Trial Update: Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of the AERAS-456 vaccine for latent tuberculosis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Tuberculosis Infection

Drugs mentioned

• AERAS-456

Snippet

Sponsor: Aeras | Conditions: Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown | Phase 1 | Status: COMPLETED | Results posted: 2019-08-21